On 1 March 2023, the PBS published its Summary of Changes, which included listing Celltrion’s Yuflyma®, biosimilar to AbbVie’s Humira® (adalimumab), on the PBS in 40mg/0.4ml pre-filled pen and syringes. This comes after Yuflyma® was recommended for PBS-listing by the Australian Pharmaceutical Benefits Advisory Council (PBAC) in its July 2022 meeting.
Yuflyma® was first approved by the TGA in March 2022 for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, enthesitis-related arthritis, psoriatic arthritis, ankylosing spondylitis. Crohn’s disease, ulcerative colitis, psoriasis, hidradenitis suppurativa and uveitis.